Cancer Patient Acceptance of HIV Screening at a Large Tertiary Cancer Center

Bruno P. Granwehr, MD,1,* Kelly W. Merriman, PhD,2 Elizabeth Y. Chiao, MD, MPH3,4 Richard M. Grimes, PhD5

1Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Tumor Registry, Division of Chief Quality Officer, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; and 4Division of General Internal Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA

*Correspondence to: Bruno P. Granwehr, MD, Department of Infectious Diseases, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1460, Houston, TX, USA (e-mail: bgranweh@mdanderson.org).

Abstract

The US Centers for Disease Control and Prevention, the US Preventive Services Task Force, and the National Comprehensive Cancer Network recommend offering HIV testing for patients presenting for cancer care. Not recognizing and treating HIV infection adversely affects both cancer treatment and HIV outcomes. Acceptance rates of oncology patients for HIV screening are not known. Our tertiary cancer center inserted language requesting permission to screen for HIV infection into the consent forms for initial presentation for cancer care. Willingness to undergo testing was examined in 29,549 consecutive new patients. These were analyzed by gender and age. Overall, 80.9% of patients agreed to HIV screening. Incorporation of language requesting permission for HIV screening into the consent form provided at presentation for cancer care relieves clinicians from adding this task.

All new patients who entered care between June 11, 2015, and March 3, 2016, were given a form that allows patients to give permission to be screened for HIV (see Figure 1), approved by the Quality Improvement Assessment Board. Forms in which a box was not selected or that were completed manually were excluded from the analysis. The forms were analyzed to determine rates of acceptance of HIV testing and were analyzed by gender and age. Overall, 80.9% of patients agreed to HIV screening. Incorporation of language requesting permission for HIV screening into the consent form provided at presentation for cancer care relieves clinicians from adding this task.

Received: November 5, 2021; Revised: May 20, 2022; Accepted: July 8, 2022

© The Author(s) 2022. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
CONSENT FOR TESTING FOR HIV: I (we) understand that if my physician, or his or her designee, thinks it is necessary, I may provide a blood sample that will be tested for HIV (the AIDS virus), or an existing blood sample may be used for this test. I (we) understand that if I test positive for HIV, the test result and my name, address, date of birth, and sex will be shared with appropriate health authorities as required by law. I (we) have indicated my (our) decision regarding HIV testing below.

[X] I DO agree to HIV testing.
[ ] I DO NOT agree to HIV testing.

Figure 1. Permission to screen for HIV in consent to diagnosis and treatment. This shows the language included in the institutional consent for diagnosis and treatment, with a check box included, requesting permission for HIV screening. If the patient does not check the box or declines HIV screening, HIV screening may still be completed but includes separate documentation.

Table 1. Rates of patient agreement with HIV screening, by age and gender

| Characteristic | Total No. | No. of patients who agreed (%) | No. of patients who did not agree (%) | P* |
|---------------|-----------|-------------------------------|--------------------------------------|----|
| Age, y        |           |                               |                                       |    |
| <20           | 644       | 462 (71.74)                   | 182 (28.26)                          |    |
| 20-29         | 1200      | 1051 (87.58)                  | 149 (12.42)                          |    |
| 30-39         | 2452      | 2076 (84.67)                  | 376 (15.33)                          |    |
| 40-49         | 4280      | 3429 (80.12)                  | 851 (19.89)                          |    |
| 50-59         | 6620      | 5281 (79.77)                  | 1339 (20.23)                         |    |
| 60-69         | 7921      | 6426 (81.13)                  | 1495 (18.87)                         |    |
| >70           | 6432      | 5167 (80.33)                  | 1265 (19.67)                         |    |
| Total         | 29549     | 23892 (80.86)                 | 5657 (19.14)                         |    |
| Gender        |           |                               |                                       |    |
| Female        | 16509     | 13360 (80.93)                 | 3149 (19.07)                         |    |
| Male          | 13040     | 10532 (80.77)                 | 2508 (19.23)                         |    |
| Total         | 29549     | 23892 (80.86)                 | 5657 (19.14)                         | .73|

* chi-squared statistic (2-sided test).

When directly comparing most age group categories, including all comparisons with patients younger than 20 years (P < .001). Of potential interest, however, is that when the youngest 3 age categories (<20 years, 20-29 years, 30-39 years) were removed, a statistically significant difference no longer remained among the remaining age groups, all older than 40 years (P = .21). In addition, there was no statistically significant difference in acceptance of HIV screening by gender, with 80.9% of females and 80.8% of males agreeing to HIV testing (P = .73; see Table 1).

Barriers that make physicians reluctant to order HIV testing include lack of patient acceptance, insufficient time for discussion, burdensome consent process, lack of knowledge or training, pretest counseling requirements, competing priorities, and inadequate reimbursement (8). This study demonstrated that there is a high level of acceptance of HIV testing by cancer patients. By having an automatic consent process at admission to care, the physician is relieved of multiple barriers to HIV routine screening. Now that HIV testing is the standard of care as recommended by the United States Preventive Services Task Force, US Centers for Disease Control and Prevention, and the National Comprehensive Cancer Network, the reimbursement issue has also been obviated because HIV testing is the standard of care. An additional incentive for oncologists is that diagnosis of HIV infection in their patients can prevent transmission of this oncogenic virus to future sexual partners as well as current partners, whom patients can encourage to get tested. This may avoid the legal complications that can arise when failure to follow the standard of care results in transmission to another person (9).

As stated by Chiao et al. (4) a dozen years ago, it is “time for oncologists to opt in for routine opt out testing.” In our institution, HIV screening was limited to only 18.6% of cancer patients who were receiving chemotherapy (10). This included 88.4% of non-Hodgkin lymphoma patients, 14% of anal cancer patients, and 9.4% of cervical cancer patients (10). HIV seropositivity was 1.2%, with 0.3% newly diagnosed (10). Without the leadership of oncologists, their patients and the partners of their patients are at risk of worse than anticipated outcomes, potential for second and recurrent cancers, and transmission of an oncogenic virus to others. “Treatment as prevention” has become a mantra in the HIV community, but this may be modified to “treatment as cancer prevention.” As an oncologist would screen renal or liver function prior to initiation of various cancer therapies, screening for HIV should also be considered standard of care. Oncologists should lead the demand for HIV testing at their institutions.

Funding
No funding was used for this study.

Notes
Role of the funder: Not applicable.
Disclosures: The authors have no disclosures.

Author contributions: Conceptualization: BG, KM, RG. Methodology: BG, KM, EC, RG. Writing - Original Draft: BG, KM, RG. Writing - Review & Editing: BG, KM, EC, RG.

Data Availability
Deidentified data may be provided on request to the corresponding author.

References
1. Moyer VA; on behalf of the U.S. Preventive Services Task Force. Screening for HIV: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(1):51-60.
2. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morb Mort Rep. 2006;55(RR14):1-17.
3. National Comprehensive Cancer Network. Cancer in people with HIV Version 2.2021. https://www.nccn.org/guidelines/category.4 Accessed July 1, 2021.
4. Chiao EY, Dezube BJ, Krown SE, et al. “Time for oncologists to opt in for routine opt-out HIV testing.” JAMA. 2010;304(3):334-339.
5. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029-1041.
6. Calkins KL, Chander G, Joshu CE, et al. Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era. JAMA Oncol. 2020;6(2):227-235.
7. Hoffmann C, Chow KI, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol. 2004;125(4):455-462.
8. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don’t physicians test for HIV? A review of the US literature. AIDS. 2007;21(12):1617-1162.
9. Grimes RM, Richards EP, Helfgott AW, Eriksen NL. Legal considerations in screening pregnant women for human immunodeficiency virus. Am J Obstet Gynecol. 1999;180(2 Pt 1):259-264.
10. Hwang JP, Granwehr BP, Torres HA, et al. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract. 2015;11(5):384-390.